As of Thursday close, Rigel Pharmaceuticals Inc.’s (NASDAQ:RIGL) stock was up $0.03, moving up 2.13 percent to $1.44. The average number of shares traded per day over the past five days has been 5,394,820 shares. 4 times new highs have been achieved over the past 5 days, with a $0.1900 gain in that time frame. In the last twenty days, the average volume was 3,759,095, while in the previous 50 days, it was 7,533,934.
Since last month, RIGL stock rose 14.29%. Shares of the company fell to $1.1100 on 07/22/22, the lowest level in the past month. A 52-week high of $4.24 was reached on 03/18/22 after having rallying from a 52-week low of $0.64. Since the beginning of this year, RIGL’s stock price has dropped by -45.66% or -$1.2100, and marked a new high 8 times. However, the stock has declined by -66.04% since its 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Rigel Pharmaceuticals Inc. (RIGL) last reported insider trading activity 57 days ago on Jun 09. RODRIGUEZ RAUL R, the CEO, President of the company, purchased of 1,000,000 shares for $0.69 on Jun 09. It resulted in a $688,400 investment by the insider.
The stock’s beta is 1.67. Besides these, the trailing price-to-sales (P/S) ratio of 3.11, the price-to-book (PB) ratio of 36.00.
In the three months ended June 29, Rigel Pharmaceuticals Inc.’s quick ratio stood at 2.20, while its current ratio was 2.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 4.38, and the total debt-to-equity ratio was 4.38. On the profitability front, the trailing twelve-month gross margin is 99.00% percent. In the year ended June 29, operating margins totaled -94.80%. Based on annual data, RIGL earned $148.15 million in gross profit and brought in $149.24 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -26.00%. Return on equity (ROE) for the past 12 months was -219.10%.
In Rigel Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $29.84 million against cash and short-term investments of $61.97 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RIGL’s revenue rose 11.9% to $16.74 million during the quarter, while net income inched up to $29.82 million. While analysts expected Rigel Pharmaceuticals Inc. to report -$0.12 quarterly earnings, the actual figure was -$0.08 per share, beating the consensus estimate by 33.30%. During the quarter, the company generated -$12.65 million in EBITDA. The liabilities of Rigel Pharmaceuticals Inc. were 131.68 million at the end of its most recent quarter ended June 29, and its total debt was $88.65 million. The value of shareholders’ equity is $172.84 million.
This quick technical analysis looks at Rigel Pharmaceuticals Inc.’s (RIGL) price momentum. With a historical volatility rate of 61.57%, the RSI 9-day stood at 65.39% on 04 August.
With respect to its five-day moving average, the current Rigel Pharmaceuticals Inc. price is up by +15.20% percent or $0.1900. At present, RIGL shares trade +9.09% above its 20-day simple moving average and -53.55% percent below its 100-day simple moving average. However, the stock is currently trading approximately -27.27% below its SMA50 and -56.76% below its SMA200.
Stochastic coefficient K was 60.18% and Stochastic coefficient D was 49.39%, while ATR was 0.1383. Given the Stochastic reading of 63.46% for the 14-day period, the RSI (14) reading has been calculated as 58.00%. As of today, the MACD Oscillator reading stands at 0.1111, while the 14-day reading stands at 0.1205.
Rigel Pharmaceuticals Inc. downgraded its rating on Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) to a Neutral in a note to investors on June 09, 2022. The analysts firm previously had a Buy rating on the stock.Rigel Pharmaceuticals Inc. (RIGL) has been rated Overweight by analysts. According to 0 brokerage firms, RIGL is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Rigel Pharmaceuticals Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $1.75, the current consensus forecast for the stock is $1.00 – $7.00. Based on these forecasts, analysts predict Rigel Pharmaceuticals Inc. (RIGL) will achieve an average price target of $2.64.